Francesca Sanvito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francesca Sanvito has a total of 601 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Naldini
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy
16 shared publications - Claudio Doglioni
Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
11 shared publications - Alessio Cantore
San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
7 shared publications - Eugenio Montini
San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy
7 shared publications - Alessandro Aiuti
Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
6 shared publications Barbara Camisa
San Raffaele Scientific Institute, Milan, Italy
6 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Oncogenic signalling and host immunocompetency govern senescent cell clearance and systemic inflammation in a mouse model of oncogene-induced senescence
Senescence is a stress-induced program defined by permanent cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype (SASP). Defective clearance of senescent cells promotes inflammation, tissue dysfunction, and ageing, yet determinants of their elimination remain poorly understood. Here, we model oncogene-induced senescence in the hematopoietic system by transplanting Braf V600E - or Braf ΔN -expressing hematopoietic stem and progenitor cells into recipients with distinct immune backgrounds. Braf V600E induces a stronger senescence program and more aggressive disease than Braf ΔN . Survival depends on oncogene-expressing cell burden and host immunity: immunocompetent, lower-burden mice clear oncogene-expressing cells and survive long-term, whereas higher-burden mice show checkpoint upregulation, T-cell exhaustion, and early death. NSG, Rag1KO, and lymphocyte-depleted hosts fail to clear these cells, developing sustained inflammation and bone marrow failure. Rapamycin administration attenuates senescence-associated features and improves survival. These findings identify oncogenic intensity and adaptive immune competence as coupled determinants of senescent-cell fate, with implications for chronic inflammation and senescence-targeted therapies.
- 20 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessOncogenic signalling and host immunocompetency govern senescent cell clearance and systemic inflammation in a mouse model of oncogene-induced senescence
Senescence is a stress-induced program defined by permanent cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype (SASP). Defective clearance of senescent cells promotes inflammation, tissue dysfunction, and ageing, yet determinants of their elimination remain poorly understood. Here, we model oncogene-induced senescence in the hematopoietic system by transplanting Braf V600E - or Braf ΔN -expressing hematopoietic stem and progenitor cells into recipients with distinct immune backgrounds. Braf V600E induces a stronger senescence program and more aggressive disease than Braf ΔN . Survival depends on oncogene-expressing cell burden and host immunity: immunocompetent, lower-burden mice clear oncogene-expressing cells and survive long-term, whereas higher-burden mice show checkpoint upregulation, T-cell exhaustion, and early death. NSG, Rag1KO, and lymphocyte-depleted hosts fail to clear these cells, developing sustained inflammation and bone marrow failure. Rapamycin administration attenuates senescence-associated features and improves survival. These findings identify oncogenic intensity and adaptive immune competence as coupled determinants of senescent-cell fate, with implications for chronic inflammation and senescence-targeted therapies.
- Open Access
- 25 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 567-582
Liver-directed lentiviral gene therapy confers durable hepatic and systemic amelioration of methylmalonic acidemia in mice
- 25 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 567-582
Open AccessLiver-directed lentiviral gene therapy confers durable hepatic and systemic amelioration of methylmalonic acidemia in mice
- 14 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (8) , 995-1010
T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication
Despite immunosensitivity, genetic heterogeneity, low mutational burden and lack of tumor-specific antigens hinder immunotherapy success for acute myeloid leukemia (AML). T cell receptors (TCRs) offer a promising route by targeting tumor-relevant extra- and intracellular antigens shared across AML subtypes; however human leukocyte antigen (HLA) restriction limits their potential. We identified a potent TCR capable of recognizing peptides of Cathepsin G (CTSG), a serine protease confined to neutrophil granules but aberrantly localized in the cytoplasm of blasts, when presented by HLA-A*24:02 and HLA-C*07:02, highly frequent alleles. Leveraging TCR gene-editing and CD8 co-receptor transduction, we engineered a robust T cell population, comprising CD4+ CD8+ T lymphocytes with enhanced functionality, without altering subset identity. T cells expressing the CTSG-TCR exhibited strong and specific cytotoxicity against primary blasts, in vitro and in vivo. Noticeably, no alterations in peripheral blood cell populations, bone marrow hematopoiesis, or extramedullary hematopoietic organs (spleen and liver) were observed, demonstrating optimal on-target/off-tumor safety profile. Moreover, the absence of off-target cross-reactivity was proved by peptide mutagenesis, highlighting the specificity of the TCR for CTSG. These results reveal the potential of dual restricted TCRs, and of CTSG-TCR T cells as powerful therapeutics for a broad AML patient population.
- 14 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (8) , 995-1010
T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication
Despite immunosensitivity, genetic heterogeneity, low mutational burden and lack of tumor-specific antigens hinder immunotherapy success for acute myeloid leukemia (AML). T cell receptors (TCRs) offer a promising route by targeting tumor-relevant extra- and intracellular antigens shared across AML subtypes; however human leukocyte antigen (HLA) restriction limits their potential. We identified a potent TCR capable of recognizing peptides of Cathepsin G (CTSG), a serine protease confined to neutrophil granules but aberrantly localized in the cytoplasm of blasts, when presented by HLA-A*24:02 and HLA-C*07:02, highly frequent alleles. Leveraging TCR gene-editing and CD8 co-receptor transduction, we engineered a robust T cell population, comprising CD4+ CD8+ T lymphocytes with enhanced functionality, without altering subset identity. T cells expressing the CTSG-TCR exhibited strong and specific cytotoxicity against primary blasts, in vitro and in vivo. Noticeably, no alterations in peripheral blood cell populations, bone marrow hematopoiesis, or extramedullary hematopoietic organs (spleen and liver) were observed, demonstrating optimal on-target/off-tumor safety profile. Moreover, the absence of off-target cross-reactivity was proved by peptide mutagenesis, highlighting the specificity of the TCR for CTSG. These results reveal the potential of dual restricted TCRs, and of CTSG-TCR T cells as powerful therapeutics for a broad AML patient population.
- Open Access
- 8 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength
T-cell avidity is a major determinant of Adoptive T cell therapy (ACT) efficacy for cancer treatment. However, high-avidity tumor-specific T cells can rarely be isolated from cancer patients, highlighting the need for strategies to enhance the cytotoxic capacity of low-avidity cells. Here, we rescue the anti-tumor functions of low-avidity T cells against pancreatic ductal adenocarcinoma (PDAC) by knocking-out TIGIT, a key inhibitory molecule expressed on exhausted CD8+ T cells infiltrating gastrointestinal tumors. We uncover that TIGIT disruption by base editing boosts the intracellular signal transduction derived from a weak T cell receptor (TCR) engagement enforcing cytoskeletal rearrangements, thus increasing T cell avidity and stabilizing the immunological synapse. Accordingly, TIGIT disruption enables low-avidity T cells to exert robust degranulation, comparable to that of high-avidity T cells, and potent and durable anti-tumor capacity in vivo in male mice. These results highlight TIGIT knockout as a potential strategy to enhance low-avidity T cell function and broaden the repertoire of TCR engineered T cells in the treatment of pancreatic cancer and other solid malignancies.
- 8 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength
T-cell avidity is a major determinant of Adoptive T cell therapy (ACT) efficacy for cancer treatment. However, high-avidity tumor-specific T cells can rarely be isolated from cancer patients, highlighting the need for strategies to enhance the cytotoxic capacity of low-avidity cells. Here, we rescue the anti-tumor functions of low-avidity T cells against pancreatic ductal adenocarcinoma (PDAC) by knocking-out TIGIT, a key inhibitory molecule expressed on exhausted CD8+ T cells infiltrating gastrointestinal tumors. We uncover that TIGIT disruption by base editing boosts the intracellular signal transduction derived from a weak T cell receptor (TCR) engagement enforcing cytoskeletal rearrangements, thus increasing T cell avidity and stabilizing the immunological synapse. Accordingly, TIGIT disruption enables low-avidity T cells to exert robust degranulation, comparable to that of high-avidity T cells, and potent and durable anti-tumor capacity in vivo in male mice. These results highlight TIGIT knockout as a potential strategy to enhance low-avidity T cell function and broaden the repertoire of TCR engineered T cells in the treatment of pancreatic cancer and other solid malignancies.
- Open Access
- 6 December 2025
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (2) , 102084
Multiple arterial aneurysms involving the thoracoabdominal aorta and renal arteries in a young patient with possible heritable etiology: Two-stage open surgical repair management
- 6 December 2025
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (2) , 102084
Open AccessMultiple arterial aneurysms involving the thoracoabdominal aorta and renal arteries in a young patient with possible heritable etiology: Two-stage open surgical repair management
- Open Access
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10384
Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
Smoldering multiple myeloma (SMM), which is in principle curable, may develop into life-threatening MM. Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may contribute to this development, but the mechanisms are unclear. Here we demonstrate that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice that exhibit SMM-like phenotypes delays the evolution to full-blown MM. Mechanistically, P. melaninogenica increases the production of short-chain fatty acids (SCFA), thereby preventing the skewing of dendritic cells towards a pro-Th17 phenotype and subsequently accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergizes with anti-PD-L1 or anti-TIGIT to suppress myeloma progression by restraining Th17 cell expansion while inducing effector CD8+ T cells. P. melaninogenica also attenuates IL-17-mediated skin lesions that mimic anti-PD-L1-induced adverse events. Our results thus suggest that gut microbiota modulation or SCFAs administration may represent treatment options for patients affected by plasma cell dyscrasias.
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10384
Open AccessMicrobiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
Smoldering multiple myeloma (SMM), which is in principle curable, may develop into life-threatening MM. Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may contribute to this development, but the mechanisms are unclear. Here we demonstrate that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice that exhibit SMM-like phenotypes delays the evolution to full-blown MM. Mechanistically, P. melaninogenica increases the production of short-chain fatty acids (SCFA), thereby preventing the skewing of dendritic cells towards a pro-Th17 phenotype and subsequently accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergizes with anti-PD-L1 or anti-TIGIT to suppress myeloma progression by restraining Th17 cell expansion while inducing effector CD8+ T cells. P. melaninogenica also attenuates IL-17-mediated skin lesions that mimic anti-PD-L1-induced adverse events. Our results thus suggest that gut microbiota modulation or SCFAs administration may represent treatment options for patients affected by plasma cell dyscrasias.
- Open Access
- 11 July 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 281
Arteriovenous malformation hemangioma of the ulnar artery: A case report highlighting challenges in diagnosis and surgical management
Background: Arteriovenous malformation hemangioma (AVMH) is a rare, benign vascular lesion, often located in the head and neck and less frequently in the limbs. Early symptoms are typically nonspecific, making the clinical differential diagnosis with other benign lesions, such as schwannomas, particularly challenging. Case Description: We report the case of a 25-year-old male presenting with a lesion in the forearm. Initially, the clinical and imaging features suggested a schwannoma, due to its location along a peripheral nerve and the absence of distinctive vascular signs. The lesion was surgically excised. Histopathological examination revealed features consistent with AVMH, confirming the diagnosis. Conclusion: This case underscores the importance of including AVMH in the differential diagnosis of soft tissue lesions, especially when located along the course of a peripheral nerve and mimicking other benign tumors such as schwannomas.
- 11 July 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 281
Open AccessArteriovenous malformation hemangioma of the ulnar artery: A case report highlighting challenges in diagnosis and surgical management
Background: Arteriovenous malformation hemangioma (AVMH) is a rare, benign vascular lesion, often located in the head and neck and less frequently in the limbs. Early symptoms are typically nonspecific, making the clinical differential diagnosis with other benign lesions, such as schwannomas, particularly challenging. Case Description: We report the case of a 25-year-old male presenting with a lesion in the forearm. Initially, the clinical and imaging features suggested a schwannoma, due to its location along a peripheral nerve and the absence of distinctive vascular signs. The lesion was surgically excised. Histopathological examination revealed features consistent with AVMH, confirming the diagnosis. Conclusion: This case underscores the importance of including AVMH in the differential diagnosis of soft tissue lesions, especially when located along the course of a peripheral nerve and mimicking other benign tumors such as schwannomas.
- Open Access
- 3 July 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1392-1409
Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering
- 3 July 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1392-1409
Open AccessSpatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering
- Open Access
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
In vivo gene therapy to the liver using lentiviral vectors (LV) may represent a one-and-done therapeutic approach for monogenic diseases. Increasing LV gene therapy potency is crucial for reducing the effective doses, thus alleviating dose-dependent toxicities and facilitating manufacturing. LV-mediated liver transduction may be enhanced by positively selecting LV-transduced hepatocytes after treatment (a posteriori) or by augmenting the initial fraction of LV-targeted hepatocytes (a priori). We show here that the a posteriori enhancement increased transgene output without expansion of hepatocytes bearing LV genomic integrations near cancer genes, in mouse models of hemophilia, an inherited coagulation disorder. Furthermore, we enhanced hepatocyte transduction a priori in mice by transiently inhibiting antiviral pathways and/or through a fasting regimen. The most promising transduction-enhancer combination synergized with phagocytosis-shielded LV, resulting in a remarkable 40-fold increase in transgene output. Overall, our work highlights the potential of minimally invasive, cost-effective treatments capable of improving the potency of in vivo LV gene therapy to hepatocytes, in order to expand its applicability and ease clinical translation.
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessEnhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
In vivo gene therapy to the liver using lentiviral vectors (LV) may represent a one-and-done therapeutic approach for monogenic diseases. Increasing LV gene therapy potency is crucial for reducing the effective doses, thus alleviating dose-dependent toxicities and facilitating manufacturing. LV-mediated liver transduction may be enhanced by positively selecting LV-transduced hepatocytes after treatment (a posteriori) or by augmenting the initial fraction of LV-targeted hepatocytes (a priori). We show here that the a posteriori enhancement increased transgene output without expansion of hepatocytes bearing LV genomic integrations near cancer genes, in mouse models of hemophilia, an inherited coagulation disorder. Furthermore, we enhanced hepatocyte transduction a priori in mice by transiently inhibiting antiviral pathways and/or through a fasting regimen. The most promising transduction-enhancer combination synergized with phagocytosis-shielded LV, resulting in a remarkable 40-fold increase in transgene output. Overall, our work highlights the potential of minimally invasive, cost-effective treatments capable of improving the potency of in vivo LV gene therapy to hepatocytes, in order to expand its applicability and ease clinical translation.
- Open Access
- 11 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-24
In vivo armed macrophages curb liver metastasis through tumor-reactive T-cell rejuvenation
Despite recent progress in cancer treatment, liver metastases persist as an unmet clinical need. Here, we show that arming liver and tumor-associated macrophages in vivo to co-express tumor antigens (TAs), IFNα, and IL-12 unleashes robust anti-tumor immune responses, leading to the regression of liver metastases. Mechanistically, in vivo armed macrophages expand tumor reactive CD8+ T cells, which acquire features of progenitor exhausted T cells and kill cancer cells independently of CD4+ T cell help. IFNα and IL-12 produced by armed macrophages reprogram antigen presenting cells and rewire cellular interactions, rescuing tumor reactive T cell functions. In vivo armed macrophages trigger anti-tumor immunity in distinct liver metastasis mouse models of colorectal cancer and melanoma, expressing either surrogate tumor antigens, naturally occurring neoantigens or tumor-associated antigens. Altogether, our findings support the translational potential of in vivo armed liver macrophages to expand and rejuvenate tumor reactive T cells for the treatment of liver metastases.
- 11 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-24
Open AccessIn vivo armed macrophages curb liver metastasis through tumor-reactive T-cell rejuvenation
Despite recent progress in cancer treatment, liver metastases persist as an unmet clinical need. Here, we show that arming liver and tumor-associated macrophages in vivo to co-express tumor antigens (TAs), IFNα, and IL-12 unleashes robust anti-tumor immune responses, leading to the regression of liver metastases. Mechanistically, in vivo armed macrophages expand tumor reactive CD8+ T cells, which acquire features of progenitor exhausted T cells and kill cancer cells independently of CD4+ T cell help. IFNα and IL-12 produced by armed macrophages reprogram antigen presenting cells and rewire cellular interactions, rescuing tumor reactive T cell functions. In vivo armed macrophages trigger anti-tumor immunity in distinct liver metastasis mouse models of colorectal cancer and melanoma, expressing either surrogate tumor antigens, naturally occurring neoantigens or tumor-associated antigens. Altogether, our findings support the translational potential of in vivo armed liver macrophages to expand and rejuvenate tumor reactive T cells for the treatment of liver metastases.